Abstract
Breast cancer resistance protein (BCRP, ABCG2) is one of the ATP binding cassette (ABC) transporter proteins which involved in multi-drug resistance of cancer therapy. BCRP is expressed in various types of human cancer and inhibiting can be a solution to overcome multidrug resistance. Significant effort has been devoted to develop treatment strategies to overcome BCRP-mediated resistance. In addition, BCRP is expressed also in many normal tissues and plays an important role in drug absorption, distribution, and elimination. In order to design an effective cancer treatment strategy, a lot of flavones and their derivatives are used as anticancer drug compounds. One of the most promising flavonols is quercetin and quercetin semisynthetic derivatives which can inhibit the expression of BCRP.
Highlights
Virtual screening using multiple docking program for consensus predictions.
Virtual screening of the quercetin derivatives as potential inhibitors of BCRP.
Selected derivatives bind to the main amino acids of proteins.
Selected derivatives meet the criteria necessary for their consideration as drugs.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
Author: Manukyan Amalya, Institute: Russian-Armenian University, Bioengineering, Bioinformatics and Molecular Biology, Street:Hovsep Emin 123 str., City:Yerevan, Country: Armenia, Email: amalimnkn{at}gmail.com